{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:30:01Z","timestamp":1791585001315,"version":"4.3.4"},"reference-count":30,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","award":["AD-1310-08215"],"award-info":[{"award-number":["AD-1310-08215"]}],"id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Urology"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p> Urinary symptoms are common for people with neurogenic lower urinary tract dysfunction (NLUTD). No nonprescription approach has been proven safe and effective for self-management of urinary symptoms. Our objective was to describe the safety and tolerability of Lactobacillus rhamnosus GG ( LGG\u00ae) instilled intravesically for self-management of inflammatory urinary symptoms in adults and children with NLUTD due to spinal cord injury or disease (SCI\/D) and who use intermittent catheterization (IC). <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p> A total of 103 individuals with SCI\/D enrolled in an 18-month study consisting of three 6-month stages: baseline (weekly observation of urinary symptoms); intervention (self-instilled intravesical LGG\u00ae in response to more cloudy or foul-smelling urine); and washout (weekly observation of urinary symptoms). Urinary symptoms were assessed using the Urinary Symptom Questionnaire for people with neurogenic bladder using intermittent catheters (USQNB-IC). Safety was based on serious adverse events and adverse events (S\/AEs) and trends in symptoms. Tolerability was defined as the independence of AE experience and willingness to use\/pay for this intervention. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p> A total of 74 (77%) adults and 6 (86%) of children completed the study, of whom 64 instilled LGG\u00ae for a total of 357 instillations (range 1\u201341\u2009per person). There were 59 S\/AEs, 44% (26\/59) of which were categorized as infectious genitourinary. There was no statistical relationship between S\/AEs and use or dose of the intervention. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p> One or two doses of self-instilled intravesical LGG\u00ae in response to more cloudy or foul-smelling urine was safe and well tolerated among this sample of adults and children with SCI\/D who have NLUTD and use IC. <\/jats:p><\/jats:sec>","DOI":"10.1177\/1756287219875594","type":"journal-article","created":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T11:27:48Z","timestamp":1570102068000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":25,"title":["Intravesical <i>Lactobacillus rhamnosus GG<\/i> is safe and well tolerated in adults and children with neurogenic lower urinary tract dysfunction: first-in-human trial"],"prefix":"10.1177","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1213-1959","authenticated-orcid":false,"given":"Suzanne L.","family":"Groah","sequence":"first","affiliation":[{"name":"MedStar National Rehabilitation Hospital, 102 Irving St, NW, Washington, DC 20010, USA"},{"name":"Department of Rehabilitation Medicine, Georgetown University Medical Center, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda K.","family":"Rounds","sequence":"additional","affiliation":[{"name":"MedStar National Rehabilitation Hospital, Washington, DC, USA"},{"name":"MedStar Health Research Health Institute, Hyattsville, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger H.","family":"Ljungberg","sequence":"additional","affiliation":[{"name":"MedStar National Rehabilitation Hospital, Washington, DC, USA"},{"name":"MedStar Health Research Health Institute, Hyattsville, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce M.","family":"Sprague","sequence":"additional","affiliation":[{"name":"Division of Urology, Children\u2019s National Health System, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie K.","family":"Frost","sequence":"additional","affiliation":[{"name":"Collaborative for Research on Outcomes and Metrics and Departments of Neurology and Biostatistics, Bioinformatics & Biomathematics, Georgetown University Medical Center, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle E.","family":"Tractenberg","sequence":"additional","affiliation":[{"name":"Collaborative for Research on Outcomes and Metrics and Departments of Neurology and Biostatistics, Bioinformatics & Biomathematics, Georgetown University Medical Center, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,10,3]]},"reference":[{"key":"bibr1-1756287219875594","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmrj.2011.01.001"},{"key":"bibr2-1756287219875594","doi-asserted-by":"publisher","DOI":"10.2340\/16501977-0067"},{"key":"bibr3-1756287219875594","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2012.11.014"},{"key":"bibr4-1756287219875594","first-page":"527","volume":"29","author":"Consortium for Spinal Cord Medicine","year":"2006","journal-title":"J Spinal Cord Med"},{"key":"bibr5-1756287219875594","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2004.03.016"},{"key":"bibr6-1756287219875594","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2012.10.037"},{"key":"bibr7-1756287219875594","doi-asserted-by":"publisher","DOI":"10.1086\/650482"},{"key":"bibr8-1756287219875594","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-0557"},{"key":"bibr9-1756287219875594","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/01952307.1992.11735873","volume":"15","author":"The prevention and management of urinary tract infections among people with spinal cord injuries","year":"1992","journal-title":"J Am Paraplegia Soc"},{"key":"bibr10-1756287219875594","first-page":"493","volume":"32","author":"Vaidyanathan S","year":"1994","journal-title":"Paraplegia"},{"key":"bibr11-1756287219875594","doi-asserted-by":"publisher","DOI":"10.1038\/sj.sc.3101565"},{"key":"bibr12-1756287219875594","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.02.980"},{"key":"bibr13-1756287219875594","doi-asserted-by":"publisher","DOI":"10.1080\/10790268.2004.11753738"},{"key":"bibr14-1756287219875594","doi-asserted-by":"publisher","DOI":"10.1159\/000049840"},{"key":"bibr15-1756287219875594","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq257"},{"key":"bibr16-1756287219875594","doi-asserted-by":"publisher","DOI":"10.1179\/107902610X12886261091839"},{"key":"bibr17-1756287219875594","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171114"},{"key":"bibr18-1756287219875594","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197568"},{"key":"bibr19-1756287219875594","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-174"},{"key":"bibr20-1756287219875594","volume-title":"Presented at the American Spinal Injury Association Annual Meeting","author":"Groah SL."},{"key":"bibr21-1756287219875594","doi-asserted-by":"publisher","DOI":"10.1080\/10790268.2019.1616456"},{"key":"bibr22-1756287219875594","doi-asserted-by":"publisher","DOI":"10.1086\/650482"},{"key":"bibr23-1756287219875594","unstructured":"CONSORT Group. Consort transparent reporting of trials, http:\/\/www.consort-statement.org\/ (accessed 19 March 2019)."},{"key":"bibr24-1756287219875594","unstructured":"US Food & Drug Administration. Safety Reporting Requirements for INDs (Investigational New Drug Applications). Safety Reporting Requirements for INDs (Investigational New Drug Applications) and BA\/BE (Bioavailability\/Bioequivalence) Studies, https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/safety-reporting-requirements-inds-investigational-new-drug-applications-and-babe. (2012, accessed 23 September 2019)"},{"key":"bibr25-1756287219875594","unstructured":"US Food and Drug Administration. CFR- code of federal regulations Title 21. US Department of Health and Human Services, Office of Disease Prevention and Health, https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/cfrsearch.cfm?fr=312.32. (accessed 5 June 2019)."},{"key":"bibr26-1756287219875594","unstructured":"European Medicines Agency. ICH Topic E9 Statistical Principles for Clinical Trials, https:\/\/www.ich.org\/products\/guidelines\/efficacy\/efficacy-single\/article\/statistical-principles-for-clinical-trials.html (1998, accessed 5 June 2019)."},{"key":"bibr27-1756287219875594","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/73.2.361s"},{"key":"bibr28-1756287219875594","doi-asserted-by":"publisher","DOI":"10.1007\/10_2008_097"},{"key":"bibr29-1756287219875594","doi-asserted-by":"publisher","DOI":"10.1007\/s003450050161"},{"key":"bibr30-1756287219875594","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-016-0136-8"}],"container-title":["Therapeutic Advances in Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756287219875594","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1756287219875594","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756287219875594","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T22:35:36Z","timestamp":1740868536000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1756287219875594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":30,"alternative-id":["10.1177\/1756287219875594"],"URL":"https:\/\/doi.org\/10.1177\/1756287219875594","relation":{},"ISSN":["1756-2872","1756-2880"],"issn-type":[{"value":"1756-2872","type":"print"},{"value":"1756-2880","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]},"article-number":"1756287219875594"}}